# EDGAR Filing Document

**Accession Number:** 0001444043
**File Stem:** 0001444043-25-000005
**Filing Date:** 2025-8
**Character Count:** 16888
**Document Hash:** c5c73b91bfdcbcc6ff3185505977800b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001444043-25-000005.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0001444043-25-000005

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250822

**EFFECTIVENESS DATE**: 20250822

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Camber Capital Management LP
- **CENTRAL INDEX KEY:** 0001444043

**ORGANIZATION NAME:**
- **EIN:** 421693587
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-13745
- **FILM NUMBER:** 251242604

**BUSINESS ADDRESS:**
- **STREET 1:** 101 HUNTINGTON AVENUE
- **STREET 2:** SUITE 2101
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02199
- **BUSINESS PHONE:** 617-717-6600

**MAIL ADDRESS:**
- **STREET 1:** 101 HUNTINGTON AVENUE
- **STREET 2:** SUITE 2101
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02199

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Camber Capital Management LLC
- **DATE OF NAME CHANGE:** 20080827

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001444043

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Camber Capital Management LP

**Address:** 101 HUNTINGTON AVENUE, BOSTON, MA 02199

**Telephone number:** 617-717-6601

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-13745

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                        | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                        | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Jazz Pharmaceuticals plc              | G50871105 | 07/25/2024     | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement.              | SECTION 14A SAY-ON-PAY VOTES |      1.11605e+06 |                0 | FOR         |                              1.11605e+06 | FOR                         |  |
| Jazz Pharmaceuticals plc              | G50871105 | 07/25/2024     | To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.  | SECTION 14A SAY-ON-PAY VOTES |      1.11605e+06 |                0 | ONE YEAR    |                              1.11605e+06 | FOR                         |  |
| Replimune Group, Inc.                 | 76029N106 | 09/04/2024     | To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers.                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.35e+06    |                0 | FOR         |                              1.35e+06    | FOR                         |  |
| Replimune Group, Inc.                 | 76029N106 | 09/04/2024     | To approve, on a non-binding advisory basis, the preferred frequency of future advisory votes on the compensation of Replimune Group, Inc.'s  named executive officers. | SECTION 14A SAY-ON-PAY VOTES |      1.35e+06    |                0 | ONE YEAR    |                              1.35e+06    | FOR                         |  |
| Medtronic Plc                         | G5960L103 | 10/17/2024     | Approving, on an advisory basis, the Company's executive compensation;                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      2.75e+06    |                0 | FOR         |                              2.75e+06    | FOR                         |  |
| Viatris Inc.                          | 92556V106 | 12/06/2024     | Approval of, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company.                                                     | SECTION 14A SAY-ON-PAY VOTES |      1.5e+07     |                0 | FOR         |                              1.5e+07     | FOR                         |  |
| Humana Inc.                           | 444859102 | 04/17/2025     | Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2025 proxy statement.                                | SECTION 14A SAY-ON-PAY VOTES | 568952           |                0 | FOR         |                         568952           | FOR                         |  |
| Pfizer Inc.                           | 717081103 | 04/24/2025     | 2025 advisory approval of executive compensation                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      5e+06       |                0 | AGAINST     |                              5e+06       | AGAINST                     |  |
| Concentra Group Holdings Parent, Inc. | 20603L102 | 05/01/2025     | Hold a non-binding advisory vote on the compensation of our named executive officers.                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      1.692e+06   |                0 | FOR         |                              1.692e+06   | FOR                         |  |
| Concentra Group Holdings Parent, Inc. | 20603L102 | 05/01/2025     | Hold a non-binding advisory vote on the frequency of the advisory vote on the compensation of our named executive officers.                                             | SECTION 14A SAY-ON-PAY VOTES |      1.692e+06   |                0 | ONE YEAR    |                              1.692e+06   | FOR                         |  |
| Baxter International Inc.             | 071813109 | 05/06/2025     | Advisory Vote to Approve Named Executive Officer Compensation for 2024                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      5.75e+06    |                0 | FOR         |                              5.75e+06    | FOR                         |  |
| ZimVie Inc.                           | 98888T107 | 05/07/2025     | Approve, on a non-binding advisory basis, named executive officer compensation ("Say on Pay").                                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.01072e+06 |                0 | FOR         |                              2.01072e+06 | FOR                         |  |
| Inogen, Inc.                          | 45780L104 | 05/14/2025     | To approve, on an advisory and non-binding basis, the compensation of our named executive officers.                                                                     | SECTION 14A SAY-ON-PAY VOTES | 986475           |                0 | FOR         |                         986475           | FOR                         |  |
| OraSure Technologies, Inc.            | 68554V108 | 05/14/2025     | Advisory (Non-Binding) Vote to Approve Executive Compensation.                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      1.38594e+06 |                0 | FOR         |                              1.38594e+06 | FOR                         |  |
| CVS Health Corporation                | 126650100 | 05/15/2025     | Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation.                                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.25e+06    |                0 | AGAINST     |                              2.25e+06    | AGAINST                     |  |
| Theravance Biopharma, Inc.            | G8807B106 | 05/19/2025     | To vote on a non-binding advisory resolution regarding the compensation of our named executive officers.                                                                | SECTION 14A SAY-ON-PAY VOTES |      1e+06       |                0 | FOR         |                              1e+06       | FOR                         |  |
| BioMarin Pharmaceutical Inc.          | 09061G101 | 05/20/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                       | SECTION 14A SAY-ON-PAY VOTES | 503500           |                0 | FOR         |                         503500           | FOR                         |  |
| Zimmer Biomet Holdings, Inc.          | 98956P102 | 05/29/2025     | Approve, on a non-binding advisory basis, named executive officer compensation ("Say on Pay").                                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.25e+06    |                0 | FOR         |                              2.25e+06    | FOR                         |  |
| 10X Genomics, Inc.                    | 88025U109 | 06/03/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                         | SECTION 14A SAY-ON-PAY VOTES |      1e+06       |                0 | AGAINST     |                              1e+06       | AGAINST                     |  |
| Apellis Pharmaceuticals, Inc.         | 03753U106 | 06/03/2025     | To hold an advisory vote to approve the compensation paid to our named executive officers;                                                                              | SECTION 14A SAY-ON-PAY VOTES | 250000           |                0 | FOR         |                         250000           | FOR                         |  |
| Apellis Pharmaceuticals, Inc.         | 03753U106 | 06/03/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and                                        | SECTION 14A SAY-ON-PAY VOTES | 250000           |                0 | ONE YEAR    |                         250000           | FOR                         |  |
| Denali Therapeutics Inc.              | 24823R105 | 06/03/2025     | Advisory vote on executive compensation                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      1.25e+06    |                0 | FOR         |                              1.25e+06    | FOR                         |  |
| Globus Medical, Inc.                  | 379577208 | 06/04/2025     | To approve, in an advisory vote, the compensation of the Company's named executive officers (the Say-on-Pay Vote).                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.5627e+06  |                0 | FOR         |                              1.5627e+06  | FOR                         |  |
| Globus Medical, Inc.                  | 379577208 | 06/04/2025     | To approve, in an advisory vote, the frequency of the approval, on an advisory basis, of the compensation of our named executive officers (the Frequency Vote).         | SECTION 14A SAY-ON-PAY VOTES |      1.5627e+06  |                0 | ONE YEAR    |                              1.5627e+06  | FOR                         |  |
| Evolent Health, Inc.                  | 30050B101 | 06/05/2025     | Proposal to approve the compensation of our named executive officers for 2024 on an advisory basis.                                                                     | SECTION 14A SAY-ON-PAY VOTES |      3e+06       |                0 | FOR         |                              3e+06       | FOR                         |  |
| Ionis Pharmaceuticals, Inc.           | 462222100 | 06/05/2025     | To make an advisory vote on executive compensation.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 725000           |                0 | FOR         |                         725000           | FOR                         |  |
| MoonLake Immunotherapeutics           | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                              | SECTION 14A SAY-ON-PAY VOTES | 441000           |                0 | FOR         |                         441000           | FOR                         |  |
| Myriad Genetics, Inc.                 | 62855J104 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.                                                | SECTION 14A SAY-ON-PAY VOTES |      2.35e+06    |                0 | FOR         |                              2.35e+06    | FOR                         |  |
| Sarepta Therapeutics, Inc.            | 803607100 | 06/05/2025     | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      1e+06       |                0 | FOR         |                              1e+06       | FOR                         |  |
| AnaptysBio, Inc.                      | 032724106 | 06/17/2025     | To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.                                  | SECTION 14A SAY-ON-PAY VOTES | 750000           |                0 | AGAINST     |                         750000           | AGAINST                     |  |
| AnaptysBio, Inc.                      | 032724106 | 06/17/2025     | Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation.                                             | SECTION 14A SAY-ON-PAY VOTES | 750000           |                0 | ONE YEAR    |                         750000           | FOR                         |  |
| PTC Therapeutics, Inc.                | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                   | SECTION 14A SAY-ON-PAY VOTES | 960000           |                0 | FOR         |                         960000           | FOR                         |  |
| Structure Therapeutics Inc.           | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                      | SECTION 14A SAY-ON-PAY VOTES | 300000           |                0 | FOR         |                         300000           | FOR                         |  |
| Structure Therapeutics Inc.           | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                 | SECTION 14A SAY-ON-PAY VOTES | 300000           |                0 | ONE YEAR    |                         300000           | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Camber Capital Management LP

**By (Signature):** Stephen DuBois

**By (Printed Signature):** Stephen DuBois

**By (Title):** Managing Member

**Date:** 08/22/2025